Sign In
Buy FRO
$40.93
+2.08 (+5.35%)
At Close: Jun 18, 2026
Frontline Q2: More Tanker Gains To Be Had
07:30am, Monday, 01'st Sep 2025
Frontline plc remains a buy, due to strong fundamentals and favorable macro trends in oil shipping, including continued profitability and a (relatively) rising dividend. The company experienced a posi
Frontline plc (FRO) Q2 2025 Earnings Call Transcript
11:52am, Friday, 29'th Aug 2025
Frontline plc (NYSE:FRO ) Q2 2025 Earnings Conference Call August 29, 2025 9:00 AM ET Company Participants Inger Marie Klemp - Chief Financial Officer of Frontline Management AS Lars H. Barstad - Chie
Frontline (FRO) Lags Q2 Earnings and Revenue Estimates
08:06am, Friday, 29'th Aug 2025
Frontline (FRO) came out with quarterly earnings of $0.36 per share, missing the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.62 per share a year ago.
FRO – Second Quarter and Six Months 2025 Results
01:30am, Friday, 29'th Aug 2025
FRONTLINE PLC REPORTS RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025 Frontline plc (the “Company”, “Frontline,” “we,” “us,” or “our”), today reported unaudited results for the
Indeavor Appoints Carter Lloyds as Chief Marketing Officer to Accelerate Growth and Champion the Frontline Workforce
08:00am, Thursday, 28'th Aug 2025
MADISON, Wis.--(BUSINESS WIRE)--Indeavor, the leader in workforce management and people operations solutions for complex, 24/7 operations, today announced the appointment of Carter Lloyds as Chief Mar
Wall Street Week Ahead
06:00am, Sunday, 24'th Aug 2025
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Frontline Education Launches AI Vision, Brought to Life by Dear Future Campaign
08:05am, Wednesday, 20'th Aug 2025
Wayne, Pa., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Frontline Education, the leading provider of administration software purpose-built for K-12, today announced the launch of its Dear Future campaign — a
Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy
04:30pm, Wednesday, 06'th Aug 2025
Safety Review Committee endorses escalation to 160 mg TUS dosing Cohorts with 120 mg, 80 mg, 40 mg TUS dosing completed with no dose-limiting toxicities Excellent safety and complete remissions (CRs)
Frontline Education Names Joel Sackett as Chief Product Officer
08:10am, Monday, 28'th Jul 2025
Wayne, Pa., July 28, 2025 (GLOBE NEWSWIRE) -- Frontline Education, a leading provider of administration software purpose-built for K-12 educators, today announced the appointment of Joel Sackett as th
24/7 Market News: Siyata Mobile Earns Verizon Frontline Verified Status, Now Protecting Communities Across All Major U.S. Networks
09:13am, Tuesday, 22'nd Jul 2025
Denver, Colorado--(Newsfile Corp. - July 22, 2025) - 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, reports that Siyata Mob
Siyata Mobile's SD7 Device Designated as "Verizon Frontline Verified"
11:04am, Wednesday, 16'th Jul 2025
Approved for Use on Verizon Frontline Network for First Responders VANCOUVER, BC , July 16, 2025 /PRNewswire/ -- Siyata Mobile Inc. (Nasdaq: SYTA, SYTAW) ("Siyata" or the "Company"), a global develope
Frontline WSIB Workers Rally at Ford's Office Amid Growing Strike Tensions
07:44pm, Wednesday, 02'nd Jul 2025
TORONTO--(BUSINESS WIRE)-- #FordNation--Harry Goslin, President of the Ontario Compensation Employees Union (OCEU/CUPE 1750), will join striking Workplace Safety and Insurance Board (WSIB) workers on
Frontline May Have Calmer Seas Ahead Of It
08:00am, Tuesday, 24'th Jun 2025
Frontline (FRO) remains a volatile but attractive long-term play, especially for investors able to stomach wild price swings and inconsistent dividends. Recent geopolitical improvements, especially th
ZIM vs. FRO: Which Shipping Company is a Stronger Play Now?
01:26pm, Monday, 23'rd Jun 2025
ZIM edges out FRO with a nimble business model, strong dividend payouts, and a superior valuation picture.
Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML
08:01am, Wednesday, 18'th Jun 2025
85% remission rate observed in evaluable frontline AML patients Mipletamig combination enables rare pathway to transplant in a previously ineligible unfit patient No dose-limiting toxicities observed
